# Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

> **NCT06231121** · — · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 13 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Faricimab

## Key facts

- **NCT ID:** NCT06231121
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-01
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-01-19
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06231121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06231121, "Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06231121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*